Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 clients • 7 examiners • 6 art units • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
ArentFox Schiff, LLP & Memorial Sloan-Kettering operates in the Biotechnology & Pharmaceuticals technology area, with 33493 career applications. This massive volume of work demonstrates extensive experience across the patent landscape. The firm is currently managing 4 pending office actions, indicating a highly focused active workload for this specific partnership.
The firm maintains a resolved allowance rate pct of 88.06, showing a high success rate across its large portfolio. Prosecution typically involves an avg office actions per allowance of 3.27. This average suggests that securing an allowance in Biotechnology & Pharmaceuticals often requires several rounds of negotiation with the USPTO.
The 88.06 resolved allowance rate pct across 33493 career applications underscores the firm's reliability as a large-scale prosecution partner. The 3.27 avg office actions per allowance provides a benchmark for clients expecting a thorough prosecution process. With 4 pending office actions, the firm continues to leverage its vast experience to achieve successful outcomes.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKINSON, PAUL W | 1 | 63.1% | +9.5% |
| ZOU, NIANXIANG | 1 | 64.1% | +24.8% |
| WHEELER, THURMAN MICHAEL | 1 | 45.8% | +23.5% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| SULLIVAN, DENNIS JOHN | 1 | 57.3% | +49.1% |
| MIDDLETON, DANAYA L | 1 | 48.5% | +49.4% |
| VU, JAKE MINH | 1 | 41.1% | +27.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17770259 | HLA CLASS I SEQUENCE DIVERGENCE AND CANCER THERAPY | MIDDLETON, DANAYA L | 5d overdue |
| 18750485 | RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS | ZOU, NIANXIANG | — |
| 18433538 | METHODS OF CANCER TREATMENT VIA REGULATED FERROPTOSIS | WHEELER, THURMAN MICHAEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17770259 | HLA CLASS I SEQUENCE DIVERGENCE AND CANCER THERAPY | MIDDLETON, DANAYA L | 5d overdue |
| 17909310 | ANTI-CCR8 AGENTS | SULLIVAN, DENNIS JOHN | 14d |
| 18750485 | RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS | ZOU, NIANXIANG | — |
| 18433538 | METHODS OF CANCER TREATMENT VIA REGULATED FERROPTOSIS | WHEELER, THURMAN MICHAEL | — |
| 17961761 | NANOPARTICLE IMMUNOCONJUGATES | HUYNH, PHUONG N | — |
| 17414414 | INDUCING FAVORABLE EFFECTS ON TUMOR MICROENVIRONMENT VIA ADMINISTRATION OF NANOPARTICLE COMPOSITIONS | VU, JAKE MINH | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Columbia University | 3 |
| MEMORIAL SLOAN KETTERING CANCER CENTER | 2 |
| THE CURATORS OF THE UNIVERSITY OF MISSOURI | 1 |
| Max-planck-gesellschaft Zur Förderung der Wissenschaften E.v. | 1 |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1619 | 1 |
| 1641 | 1 |
| 1642 | 1 |
| 1674 | 1 |
| 1618 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18911705 | NANOPARTICLE DRUG CONJUGATES | Cornell University | DICKINSON, PAUL W | §102§103§112DP | Non-Final OA | — | Pending | Oct 10, 2024 | |
| 18750485 | RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS | Memorial Sloan Kettering Cancer Center | ZOU, NIANXIANG | 1671 | §103§112Other | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18433538 | METHODS OF CANCER TREATMENT VIA REGULATED FERROPTOSIS | Cornell University | WHEELER, THURMAN MICHAEL | 1619 | §102§103§112 | Non-Final OA | — | Pending | Feb 06, 2024 |
| 17961761 | NANOPARTICLE IMMUNOCONJUGATES | The Curators of the University of Missouri | HUYNH, PHUONG N | 1641 | §112DP | Final Rejection | — | Pending | Oct 07, 2022 |
| 17909310 | ANTI-CCR8 AGENTS | Memorial Sloan Kettering Cancer Center | SULLIVAN, DENNIS JOHN | 1642 | §112 | Final Rejection | 14d | Pending | Sep 02, 2022 |
| 17770259 | HLA CLASS I SEQUENCE DIVERGENCE AND CANCER THERAPY | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MIDDLETON, DANAYA L | 1674 | §101§112 | Non-Final OA | 5d overdue | Pending | Apr 19, 2022 |
| 17414414 | INDUCING FAVORABLE EFFECTS ON TUMOR MICROENVIRONMENT VIA ADMINISTRATION OF NANOPARTICLE COMPOSITIONS | Cornell University | VU, JAKE MINH | 1618 | §103Other | Non-Final OA | — | Pending | Jun 16, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial